Idera Pharmaceuticals (NASDAQ: IDRA) is one of 191 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Idera Pharmaceuticals to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.

Profitability

This table compares Idera Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Idera Pharmaceuticals -313.78% -60.80% -55.07%
Idera Pharmaceuticals Competitors -3,316.35% -533.27% -39.75%

Earnings and Valuation

This table compares Idera Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Idera Pharmaceuticals $16.20 million -$38.38 million -6.73
Idera Pharmaceuticals Competitors $213.37 million -$39.02 million -62.50

Idera Pharmaceuticals’ competitors have higher revenue, but lower earnings than Idera Pharmaceuticals. Idera Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Idera Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals’ competitors have a beta of 1.52, indicating that their average stock price is 52% more volatile than the S&P 500.

Institutional and Insider Ownership

24.3% of Idera Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 30.3% of Idera Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Idera Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Idera Pharmaceuticals 0 0 6 0 3.00
Idera Pharmaceuticals Competitors 512 2432 6621 122 2.66

Idera Pharmaceuticals presently has a consensus price target of $5.40, suggesting a potential upside of 143.24%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.92%. Given Idera Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Idera Pharmaceuticals is more favorable than its competitors.

Summary

Idera Pharmaceuticals beats its competitors on 8 of the 12 factors compared.

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.